http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004063739-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2001-10-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afffa210626831fc1e904bf582f0d93f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48afa32359256563813d0e6be3f6fc9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e708c04553b412eaf7415867aca15f4 |
| publicationDate | 2004-04-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2004063739-A1 |
| titleOfInvention | N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents |
| abstract | The present invention pertains to certain N 8 ,N 13 -disubstituted quino[4,3,2-kl]acridinium salts of formula (Q − ) which inhibit telomerase wherein: p is an integer from 0 to 4; q is an integer from 0 to 3; r is an integer from 0 to 4; each R A is —H or a ring substituent; each R B is —H or a ring substituent; each R C is —H or a ring substituent; R N8 is a nitrogen substituent; R N13 is a nitrogen substituent; and, Q is an anion. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative conditions, such as cancer. |
| priorityDate | 2000-10-12^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 1000 of 1676.
| Next Page | Last Page |